• Publications
  • Influence
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
CONTEXT Activation of the coagulation system and depletion of endogenous anticoagulants are frequently found in patients with severe sepsis and septic shock. Diffuse microthrombus formation mayExpand
  • 547
  • 23
  • PDF
High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial
ContextActivation of the coagulation system and depletion of endogenous anticoagulants are frequently found in patients with severe sepsis and septic shock. Diffuse microthrombus formation may induceExpand
  • 1,120
  • 13
  • PDF
Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial
Summary.  Background: Prothrombin complex concentrate (PCC) can substantially shorten the time needed to reverse antivitamin K oral anticoagulant therapy (OAT). Objectives. To determine theExpand
  • 288
  • 11
Antithrombin, heparin, and heparan sulfate
ObjectivesTo review the experimental and clinical evidence that antithrombin has multiple mechanisms for both its anticoagulant and anti-inflammatory properties. The interaction between antithrombinExpand
  • 121
  • 6
Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A
Haemophilia A is treated with FVIII, either prophylactically or on demand. Prophylaxis is the gold standard in children and evidence is accumulating in adults.
  • 26
  • 3
Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate
Prothrombin complex concentrate (PCC) infusion is preferred for emergency reversal of coumarin therapy. Rapid infusion can potentially save crucial time; however, the possible impact of high infusionExpand
  • 52
  • 1
Antithrombin III in patients with severe sepsis: a pharmacokinetic study
Objectives: To evaluate the safety, pharmacokinetics, and the practicability of two different antithrombin III (AT III) high-dose regimens in patients with severe sepsis.¶Design: Prospective, open,Expand
  • 55
  • 1
Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program
Simoctocog alfa (human-cl rhFVIII, Nuwiq®) is a 4th generation recombinant FVIII (rFVIII), without chemical modification or fusion with any other protein/fragment. Nuwiq® is produced in a humanExpand
  • 3
  • 1
Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]
IntroductionTreatment of sepsis is aimed at increasing both the duration and quality of survival. A long-term focus on quality of life (QoL) in clinical trial evaluations of sepsis care should be aExpand
  • 40
Localization of platelet‐derived growth factor receptor subunit expression in chronic venous leg ulcers
Cellular responses to platelet‐derived growth factor, which affects all phases of the wound healing process, are dependent on the interaction of the growth factor with its cell surface receptors.Expand
  • 12